Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Context Therapeutics Inc. (CNTX)

Context Therapeutics Reports Positive Interim Phase 1 Data for CTIM-76

Positive Impact 4 of 5 product/contract Written later

Context Therapeutics filed a press release and conference call materials on interim Phase 1a data for CTIM-76, its Claudin 6 x CD3 bispecific antibody, which the company describes as showing efficacy and safety signals in heavily pretreated patients. The sample is small (13 patients in all comers and 10 RECIST-evaluable at target doses, as of May 29, 2026), and the company states that clinical data are preliminary. The company also expects cash runway into mid-2027 and anticipates further CTIM-76 data in Q4 2026.

Key points

  • As of May 29, 2026, 2 of 10 RECIST-evaluable patients at target doses (140 to 280 µg) had confirmed overall response, and 5 of 10 had disease control.
  • Grade 1 cytokine release syndrome (CRS) was reported in 16% of all-comers patients (n=13) at target doses, with no Grade 2 or higher CRS in that group.
  • Updated CTIM-76 data are anticipated in Q4 2026, and preliminary Phase 1a data for the CT-95 mesothelin program are expected in September 2026.
  • The company expects cash runway into mid-2027.

The filing

CompanyContext Therapeutics Inc. (CNTX)
Form8-K, current report
Filed with the SECJun 15, 2026, 9:18 AM ET
Accession number0001628280-26-043042

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 15, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.